Biomedical Research Center of the Slovak Academy of Sciences

1 article published in JoVE

• Cancer Research

  
  Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue Jesús Frutos Díaz-Alejo*^1,2,3,4, Simon April-Monn*⁵, Marina Cihova⁶, Verona Buocikova⁶, Jorge Villalón López^1,3, Maria Urbanova⁶, Carmen G. Lechuga⁷, Miroslav Tomas^6,8, Peter Dubovan^6,8, Bárbara Luna Sánchez³, Sonia Camaño Páez³, Alfonso Sanjuanbenito^2,9, Eduardo Lobo⁹, Estefanía Romio de la Heras¹⁰, Carmen Guerra^2,7, Carolina de la Pinta¹¹, Emma Barreto Melian^1,2, Mercedes Rodríguez Garrote^1,2, Alfredo Carrato^1,2,4, Laura Ruiz-Cañas^3,12,13, Bruno Sainz, Jr.^2,3,12,13, Ana Torres³, Bozena Smolkova⁶, Julie Earl^{1,2,3 1}Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS), ²The Biomedical Research Network in Cancer (CIBERONC), ³Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS), ⁴Faculty of Medicine, University of Alcalá de Henares, ⁵Institute of Tissue Medicine and Pathology, University of Bern, ⁶Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, ⁷Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), ⁸Department of Surgical Oncology, National Cancer Institute, Slovak Medical University, ⁹Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal, ¹⁰Department of Pathology, Hospital Universitario Ramón y Cajal, ¹¹Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, ¹²Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), ¹³Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS Tumor organoids have revolutionized cancer research and the approach to personalized medicine. They represent a clinically relevant tumor model that allows researchers to stay one step ahead of the tumor in the clinic. This protocol establishes tumor organoids from fresh pancreatic tumor tissue samples and patient-derived xenografts of pancreatic adenocarcinoma origin.